BB Biotech AG (BB.XMIL) DCF Valuation
Every assumption below is yours to change. The defaults are derived from this company's own filing history, not from a house view.
Conservative
CHF 111.46
0% undervaluedvs CHF 0.00
Base
CHF 194.10
0% undervaluedvs CHF 0.00
Optimistic
CHF 315.60
0% undervaluedvs CHF 0.00
Where today's price sits
Today's price falls outside the modelled range.
Base free cash flow
CHF 394M
Trailing twelve months
Historical FCF CAGR
+14.2%
Across 6 reported periods
Market implies
—
No solution in range
Terminal value share
66%
Of the base case valuation
Growth needed to justify today's price
No growth rate in the tested range reproduces today's price at these assumptions.
Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.
Free cash flow history
The most recent period is the base every projection starts from. Compounded, that history is +14.2% a year.
BB Biotech (BB.XMIL) DCF: intrinsic value and margin of safety
Intrinsiqq's two-stage DCF values BB Biotech (BB.XMIL) at about CHF 258.80 per share, or CHF 194.10 with a 25% margin of safety. Every assumption is adjustable below; this is analysis, not investment advice.
Frequently asked
What is BB Biotech's (BB.XMIL) fair value?+
Intrinsiqq's two-stage discounted cash flow (DCF) model estimates an intrinsic value of about CHF 258.80 per share for BB.XMIL. It projects recent free cash flow forward at a growth rate that fades toward a long-run rate, then discounts those cash flows back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around CHF 194.10. The output moves with the growth and discount-rate inputs, so it is best read as a range, not a single number. You can change every assumption with the sliders on this tab.
What growth is priced into BB Biotech?+
The base case grows BB.XMIL's free cash flow at about 14.2% a year before fading, against roughly 14.2% historical free-cash-flow growth. If the price implies growth well above what the company has actually delivered, the market is paying for optimism; if below, expectations are modest. Adjust the growth assumption on this tab to see what the current price is really betting on.
What is a good margin of safety for BB Biotech?+
A margin of safety is the discount to intrinsic value you demand before buying, to protect against being wrong on the inputs. Intrinsiqq applies 25% by default, which turns BB.XMIL's CHF 258.80 intrinsic estimate into a CHF 194.10 entry. Wider margins suit less predictable businesses; you can set your own on this tab. This is analysis from company filings, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BB.XMIL
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.